FDA · Life Science & Pharma: GxP - CSV & Data Integrity
Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations (FDA guidance)
Final Quality foundations · Guidance Last verified: not yet · Source last checked 3 Nov 2026
- Issued by
- FDA
- Category
- Quality foundations
- Sub Category
- Guidance
- Legal weight
- Guidance & Q&A
- Reuse
- Public domain
FDA's guidance showing how a modern quality system fits with the US drug GMP rules.
How to read this page
- The line under the title explains in plain words what this item is for. The coloured label beside its status gives its Category, its main subject, and Sub Category, the type of document, in the same colours as the maps.
- Status comes from the latest dated event below, and each event links to its source.
- Lifecycle shows the steps so far, then any expected target. Targets are not facts.
- In plain English is our own summary, not the official text. Where we have read the document in detail, a fuller profile follows, with its context, scope, contents and key points.
- Related shows links to other documents. Select Compare to see two side by side.
Lifecycle
Solid steps have happened. A dashed step is expected, and it is not a fact. Only dated steps in our record appear here.
- Final guidance issued
In plain English
FDA guidance to help manufacturers use modern quality systems and risk management to meet the CGMP regulations in 21 CFR parts 210 and 211.
Summary drafted with AI assistance. Not yet reviewed by the SME Reviewer. Read the official text before acting.
Context and history
FDA issued this guidance on 2 October 2006 to help manufacturers use modern quality systems and risk management to meet the drug CGMP rules. It shows how a quality systems model fits with parts 210 and 211.
Who and what it applies to
Manufacturers of human and veterinary drugs, including biological products, under parts 210 and 211.
What it contains
- Background and purpose
- Why FDA promotes modern quality systems, and how this guidance relates to CGMP.
- CGMPs and modern quality systems
- Quality, quality by design and product development, quality risk management, CAPA, change control, the quality unit, and the six-system inspection model.
- Management responsibilities
- Provide leadership, structure the organisation, build the quality system, set policies and objectives, and review the system.
- Resources
- General arrangements, personnel development, facilities and equipment, and control of outsourced operations.
- Manufacturing
- Design and document products and processes, examine inputs, perform and monitor operations, and address nonconformities.
- Evaluation activities
- Analyse data for trends, conduct internal audits, use quality risk management, and take corrective action, preventive action and improvement steps.
Key points
- A quality system complements CGMP, and does not replace it.
- Management is expected to lead.
- The model extends to outsourced operations.
- Its six-system inspection model explains how FDA looks at a firm.
- FDA cited it in the 2026 warning letter on AI use.
In practice
General reading, not advice. This is drafted with AI and may not fit your situation. It does not replace the official text, your own quality system or qualified advice, and an inspector may take a different view.
- Use its four parts to place computerised systems and data integrity inside your quality system.
- Use trend analysis of audit trail and deviation data as evidence of evaluation.
Read from the source document on 1 Nov 2026. This is our own description, not the official text. Check the full dated history in the change log below.
Change log
Key dated events only, not a complete history. Status after is the status once that event happened. Event kinds explained
| Date | Event | Status after | Source |
|---|---|---|---|
| 2 Oct 2006 | Final guidance issued | Final | Source for Final guidance issued |
Related
How other documents connect to this one. Links explained
- Interprets 21 CFR Part 211· Compare with 21 CFR Part 211 Unverified link
- Risk basis from ICH Q9(R1)· Compare with ICH Q9(R1) Unverified link
Official source
The official text always prevails over anything on this site.
Source: FDA. Public domain.
Stay updated
Newsletter signup opens at launch.